arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Processa Pharmaceuticals, Inc.

PCSA
$1.89 ▼ -0.01 (-0.53%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
57 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome

Analytical Summary

Processa Pharmaceuticals, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $5.2M
Dividend Yield
Revenue Growth None
Op. Margin
ROIC 581.6%
FCF / Share $-0.73
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

57-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-3.38M
↓ -19.1%
FCF / Share Free cash flow per share
$-0.73
↑ +47.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
1
Financial Health
2
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 57 quarters